Cagrilintide vs CJC-1295 (without DAC)
Extensively Studied vs Well Studied
synergistic Mechanism-based · 51% Cagrilintide helps counteract the insulin-disrupting effects of CJC-1295 (without DAC). A smart combination — the insulin sensitizer mitigates metabolic side effects.
Molecular Data
Cagrilintide CJC-1295 (without DAC)
Weight 4,409.01 Da 3,367.97 Da
Half-life ~7 days (159-195 hours) 30 minutes - 2 hours
Chain 37 amino acids 30 amino acids
Type Amylin receptor agonist GHRH analog
Key Benefits
Cagrilintide
01 FDA development candidate with extensive Phase 3 data
02 Superior weight loss in combination with semaglutide (22.7%)
03 Once-weekly convenience
04 2.2% HbA1c reduction with CagriSema
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
Dosing Protocols
Cagrilintide
2.4mg weekly (after escalation) / Once weekly, same day each week
Weight Loss (Monotherapy) 2.4mg Once weekly
Weight Loss (CagriSema) 2.4mg + semaglutide 2.4mg Once weekly
Type 2 Diabetes Management 2.4mg weekly Once weekly
Dose Escalation Protocol 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg Weekly increases over 16 weeks
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
Side Effects
Cagrilintide
Gastrointestinal effects (nausea, vomiting, diarrhea) during initial weeks
Anti-cagrilintide antibodies develop in 46-73% but do not affect efficacy
Only 57.3% achieved maximum 2.4mg dose in REDEFINE 1 trial
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
Contraindications
Not recommended in pregnancy or breastfeeding
Not yet commercially available (FDA approval expected Q1 2026)
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Research Evidence
Cagrilintide CJC-1295 (without DAC)
Status Extensively Studied Well Studied
References 3 studies 5 studies
Latest December 2025 November 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.